Economic aspects of epilepsy and antiepileptic treatment: A review of the literature

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 5, Issue 3, 2005, Pages 327-338

  Pillas, Demetris ^a   Selai, Caroline ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cost benefit; Cost minimization; Cost of epilepsy; Cost of illness; Cost of treatment; Cost effectiveness; Cost utility

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADD ON THERAPY; BRAIN SURGERY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG PREFERENCE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; GEOGRAPHY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HOSPITAL COST; HUMAN; INCIDENCE; LONG TERM CARE; MEDLINE; META ANALYSIS; PATIENT SATISFACTION; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; SOCIOECONOMICS; SYSTEMATIC REVIEW; TEMPORAL LOBECTOMY; VAGUS NERVE STIMULATION;

EID: 21244437575     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.5.3.327     Document Type: Review

References (57)

1. Adams RD, Victor M, Ropper AH. Principles of Neurology, Sixth Edition. Mc Graw-Hill, NY, USA, 313 (1997).
2. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J. Neurol. Neurosurg. Psychiatry 61, 433-443 (1996).
3. Sander JW. The epidemiology of epilepsy revisited. Curr. Opin. Neurol. 16, 165-170 (2003).
4. Heaney DC, Macdonald BK, Everitt A et al. Socioeconomic variation in incidence of epilepsy: prospective community based study in southeast England. Br. Med. J. 325, 1013-1016 (2002).
5. Leary LD, Morrell MJ. Update on new antiepileptic drugs in children. Primary Psychiatry 11(4), 40-45 (2004).
6. Spencer S. Long-term outcome after epilepsy surgery. Epilepsia 37, 807-813 (1996).
7. Schachter SC, Wheless JW. Vagus nerve stimulation 5 years after approval: a comprehensive update. Neurology 59(4), S15-S20 (2002).
8. Beran RG. Economic analysis of epilepsy care. Epilepsia 40(8), 19-24 (1999).
9. Al-Zakwani I, Hanssens Y, Deleu D et al. Annual direct medical cost and contributing factors to total cost of epilepsy in Oman. Seizure 12, 555-560 (2003).
10. Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 45, 171-178 (2004).
11. Begley CE, Famulari M, Annegers JF et al. The cost of epilepsy in the United Sates: an estimate from population-based clinical and survey data. Epilepsia 41, 342-351 (2000).
12. Begley CE, Lairson DR, Reynolds TF, Coan S. Early treatment cost in epilepsy and how it varies with seizure type and frequency. Epilepsy Res. 41, 205-215 (2001).
13. Berto P, Tinuper P, Viaggi S et al. Cost-of-illness of epilepsy in Italy. Data from a multicentre observational study (Episcreen). Pharmacoeconomics 17, 197-208 (2000).
14. de Zélicourt M, Bureau L, Fagnani F, Jallon P. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic Seizures (the CAROLE study). Seizure 9, 88-95 (2000).
15. Frost FJ, Hurley JS, Petersen HV, Gunter MJ, Gause D. A comparison of two methods for estimating the healthcare costs of epilepsy. Epilepsia 41, 1020-1026 (2000).
16. Garattini L, Ricci E, Roggeri D, Tediosi F, Beghi E, Parazzini F. Costs of epilepsy care in referral centers in Italy. Eur. J. Health Econ. 19, 87-99 (2000).
17. Guerrini R, Battini R, Ferrari AR et al. The costs of childhood epilepsy in Italy: comparative findings from three healthcare settings. Epilepsia 42, 641-646 (2001).
18. Halpern M, Rentz A, Murray M. Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates. Neuroepidemiology 19, 87-99 (2000).
19. Jacoby A, Buck D, Baker G, McNamee P, Graham-Jones S, Chadwick D. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 39, 776-786 (1998).
20. Kotsopoulos IA, Evers SM, Ament AJ et al. The costs of epilepsy in three different populations of patients with epilepsy. Epilepsy Res. 54, 131-140 (2003).
21. Krishnan A, Sahariah SA, Kapoor SK. Cost of epilepsy in patients attending a secondary-level hospital in India. Epilepsia 45, 289-291 (2004).
22. Mak W, Fong JK, Cheung RT, Ho ST. Cost of epilepsy in Hong Kong: experience from a regional hospital. Seizure 8, 456-464 (1999).
23. Nsengiyumva G, Druet-Cabanac M, Nzisabira L, Preux P, Vergnenegre A. Economic evaluation of epilepsy in Kiremba (Burundi): a case-control study. Epilepsia 45, 673-677 (2004).
24. Tetto A, Manzoni P, Millul A et al. The costs of epilepsy in Italy. A prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res. 48, 207-216 (2002).
25. Thomas SV, Sarma PS, Alexander M et al. Economic burden of epilepsy in India. Epilepsia 42, 1052-1060 (2001).
26. Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 39(3), S19-S25 (1998).
27. Heaney DC, Shorvon SD, Sander JW et al. Cost minimization analysis of anti-epileptic drugs in newly diagnosed epilepsy in 12 European countries. Epilepsia 41(5), S37-S44 (2000).
28. Radhakrishnan K, Nayak S, Kumar S, Sarma P. Profile of anti-epileptic pharmacotherapy in a tertiary referral center in South India: a pharmacoepidemiological and pharmacoeconomic study. Epilepsia 40, 179-185 (1999).
29. Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost-minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 7, 119-125 (1998).
30. Markowitz MA, Mauskopf JA, Halpern MT. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology 51, 1026-1033 (1998).
31. Platt M, Sperling M. A comparison of surgical and medical costs for refractory epilepsy. Epilepsia 43(4), S25-S31 (2002).
32. Rao MB, Radhakrishnan K. Is epilepsy surgery possible in countries with limited resources? Epilepsia 41(4), S31-S34 (2000).
33. Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure 8, 8-13 (1999).
34. Selai CE, Trimble MR, Lavett J. Pharmacoeconomics: a cost-effectiveness study of four anti-epileptic drugs. In: Benzodiazepines. Trimble MR, Hindmarch I (Eds), Wrightson Biomedical Publishing, Petersfield, UK, 131-146 (2000).
35. van Hout BA, Gagnon DD, McNulty P, O'Hagan A. The cost-effectiveness of two new anti-epileptic therapies in the absence of direct comparative data. Pharmacoeconomics 21, 315-326 (2003).
36. Boon P, Vonck K, Vandekerckhove T et al. Vagus nerve stimulation for refractory epilepsy; efficacy and cost-benefit analysis. Acta Neurochir. 141, 447-453 (1999).
37. Boon P, D'Have M, Van Walleghem P et al. Direct costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia 43, 96-102 (2002).
38. Forbes RB, Macdonald S, Eljamel S, Roberts RC. Cost-utility analysis of vagus nerve stimulators for adults with medically refractory epilepsy. Seizure 12, 249-256 (2003).
39. Messori A, Trippoli S, Becagli P et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur. J. Clin. Pharmacol. 53, 421-427 (1998).
40. Annegers JF, Beghi E, Begley CE. Cost of epilepsy: contrast of methodologies in United States and European studies. Epilepsia 40(8), S14-S18 (1999).
41. Begley CE, Annegers JF, Lairson DR, Reynolds TF. Estimating the cost of epilepsy. Epilepsia 40(8), S8-S13 (1999).
42. Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia 43(4), S3-S9 (2002).
43. Brunetti M, Pagano E, Garattini L. The economic cost of epilepsy: a review. Ital. J. Neurol. Sci. 19, 116-119 (1998).
44. Heaney DC, Sander JW. Ensuring appropriate care in epilepsy: an overview of epidemiological and cost of illness considerations. Dis. Manage Health Outcomes 4, 303-313 (1998).
45. Kotsopoulos IA, Evers SM, Ament AJ, de Krom MC. Estimating the costs of epilepsy: an international comparison of epilepsy cost studies. Epilepsia 42, 634-640 (2001).
46. Langfitt JT. Cost evaluations in epilepsy: an update. Epilepsia 41(2), S62-S68 (2000).
47. Levy P. Economic evaluation of anti-epileptic drug therapy: a methodologic review. Epilepsia 43, 550-558 (2002).
48. Heaney D. The pharmacoeconomics of the new anti-epileptic drugs. Epilepsia 40(8), S25-S31 (1999).
49. Levy P. Pharmacoeconomic evaluation of medical treatment of epilepsy: where do we stand? Acta Neurol. Belg. 99, 239-246 (1999).
50. Heaney DC, Sander JA, Shorvon SD. Comparing the cost of epilepsy across eight European countries. Epilepsy Res. 43, 89-95 (2001).
51. Schlienger RG, Oh PI, Knowles SR, Shear NH. Quantifying the costs of serious adverse drug reactions to anti-epileptic drugs. Epilepsia 39(7), S27-S32 (1998).
52. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 37(2), S18-S22 (1996).
53. Matsuo F, Bergen D, Faught E et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 43, 2284-2291 (1993).
54. Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 35, 1230-1243 (1994).
55. Stavem K. Quality of life in epilepsy: comparison of four preference measures. Epilepsy Res. 29, 201-209 (1998).
56. Remak E, Hutton J, Selai CE, Trimble MR, Price MJ. A cost-utility analysis of adjunctive treatment with newer anti-epileptic drugs in the UK. J. Med. Econ. 7, 29-40 (2004).
57. Begley CE, Beghi E, Beran R et al. ILAE Commission on the burden of epilepsy, Subcommission on the economic burden of epilepsy: final report 1998-2001. Epilepsia 43, 668-673 (2002).